Design of a Trivalent DC-inducing mRNA Vaccine Against Monkeypox, Cowpox, and Vaccinia Viruses: A Computational Approach
Abstract
Background: Monkeypox virus (MPXV) is a novel virus that has been disseminated around the globe and caused human disease. Over 86 thousand infection cases have been reported, which has concerned the World Health Organization (WHO). Given the challenges faced due to the spread of MPXV, an immune-mediating therapy to prevent infection by MPXV is invaluable to aid large-scale public health practices. In this field, the mRNA vaccine could be a sufficient way to control the virus's transmissibility around worldwide study; we used immunoinformatic approaches that aided the pathway to develop the novel mRNA vaccine.
Methods: In the first step, we gathered three key proteins (A35R, cell surface binding, and M1R) conserved in Cowpox as well as Vaccinia viruses for the design of vaccines and computed the potent immunogen epitopes that the engineered vaccines assemble with the fused finalized epitopes and Beta-defensin 3 adjuvant that is a major stimulation of dendritic cells (DCs), along with the PADRE and TAT sequences were added. The vaccine construct was modeled with Robetta tool and validated by PROCHECK, ERRAT, and Z-score. Physicochemical properties were also investigated and confirmed to be favorable. Disulfide engineering, immunological simulation, and molecular docking with TLR3 were performed. Finally, the construction of mRNA was designed in silico, the mRNA vaccine structure was predicted, and then the molecular dynamics simulation was performed to investigate the TLR3-vaccine complex.
Results: The eighteen final epitopes were predicted. The engineered multi-epitope protein, entails 350 amino acids and had good structural quality, as quantified through an ERRAT value over 99%. Also, engineering of disulfide bond was performed in order to augment the construct stability of the MPXV vaccine. The Ramachandran analysis was utilized to further corroborate the favorable φ (phi) and ψ (psi) angles, with the aminoacids localized to the highly favorable or permitted regions. The design of the mRNA construct was achieved by incorporating the 5’UTR, start codon, signal peptide, open reading frames, stop codon,3’UTR, and polyA. In addition, the immune simulation showed sustained immune response. Also, the molecular dynamic simulation (MDS) and energy analyses suggested that the vaccine-TLR3 complex binding was stable.
Conclusion: An mRNA vaccine was designed to provoke a robust immune response against MPXV while offering immunoprotection against Cowpox and Vaccinia. The present work analyzed the structure of a novel multi-epitope vaccine, which indicated it could be an effective option against MPXV infection. Future study is recommended to confirm the immunomodulatory role of the designed MPXV vaccine.
1. Alakunle E, Moens U, Nchinda G, Okeke MI. Monkeypox Virus in Nigeria: Infection Biology, Epidemiology, and Evolution. Viruses. 2020;12(11).
2. Shchelkunov SN, Totmenin A V, Safronov PF, Mikheev M V, Gutorov V V, Ryazankina OI, et al. Analysis of the monkeypox virus genome. Virology. 2002 Jun;297(2):172–94.
3. Cho CT, Wenner HA. Monkeypox virus. Bacteriol Rev. 1973 Mar;37(1):1–18.
4. Marennikova SS, Moyer RW. Classification of Poxviruses and Brief Characterization of the Genus Orthopoxvirus. In: Orthopoxviruses Pathogenic for Humans. Boston, MA: Springer US; 2005. p. 11–8.
5. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022 Feb;16(2):e0010141.
6. Kozlov M. Monkeypox outbreaks: 4 key questions researchers have. Vol. 606, Nature. England; 2022. p. 238–9.
7. Vogel L. Making sense of monkeypox death rates. CMAJ. 2022 Aug;194(31):E1097.
8. Muniandy T, Abdullah N. Monkeypox: A Comprehensive Review. International Journal of Online Pedagogy and Course Design. 2022;13(1):1–15.
9. Schmidt FI, Bleck CKE, Mercer J. Poxvirus host cell entry. Curr Opin Virol. 2012;2(1):20–7.
10. Banuet-Martinez M, Yang Y, Jafari B, Kaur A, Butt ZA, Chen HH, et al. Monkeypox: a review of epidemiological modelling studies and how modelling has led to mechanistic insight. Epidemiol Infect. 2023 May;151:e121.
11. Zovi A, Ferrara F, Langella R, Vitiello A. Pharmacological Agents with Antiviral Activity against Monkeypox Infection. Int J Mol Sci. 2022 Dec;23(24).
12. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 2000 Jan;266(2):329–39.
13. Hou F, Zhang Y, Liu X, Murad Y, Xu J, Yu Z, et al. Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge. bioRxiv. 2022;
14. Sagdat K, Batyrkhan A, Kanayeva D. Exploring monkeypox virus proteins and rapid detection techniques. Front Cell Infect Microbiol. 2024;14:1414224.
15. Saleki K, Mohamadi MH, Alijanizadeh P, Rezaei N. Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol. 2023;19(11):1361–83.
16. Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Afsharian M, Saleki K, Barary M, et al. Vaccine‐induced immune thrombotic thrombocytopenia after vaccination against Covid‐19: a clinical dilemma for clinicians and patients. Rev Med Virol. 2022;32(2):e2273.
17. Saleki K, Payandeh P, Shakeri M, Pourahmad R, Banazadeh M, Alijanizadeh P, et al. Utilizing immunoinformatics to target brain tumors; an aid to current neurosurgical practice. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
18. Khan S, Khan A, Rehman AU, Ahmad I, Ullah S, Khan AA, et al. Immunoinformatics and structural vaccinology driven prediction of multi-epitope vaccine against Mayaro virus and validation through in-silico expression. Infect Genet Evol. 2019 Sep;73:390–400.
19. Omoniyi AA, Adebisi SS, Musa SA, Nzalak JO, Danborno B, Bauchi ZM, et al. Designing a multi-epitope vaccine against the Lassa virus through reverse vaccinology, subtractive proteomics, and immunoinformatics approaches. Inform Med Unlocked. 2021;25:100683.
20. Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ, et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jun;71(22):734–42.
21. Babkin I V, Babkina IN, Tikunova N V. An Update of Orthopoxvirus Molecular Evolution. Viruses. 2022 Feb;14(2).
22. Home M, Populations S. Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Mpox Outbreak | Mpox | Poxvirus | CDC. 2023;(Cdc):28–30.
23. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science (1979). 2021;374(6572):abm0829.
24. Al Tbeishat H. Novel In Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications. Sci Rep. 2022 Mar;12(1):4645.
25. Saleki K, Alijanizade P, Moradi S, Rahmani A, Banazadeh M, Mohamadi MH, et al. Engineering a novel immunogenic chimera protein utilizing bacterial infections associated with atherosclerosis to induce a deviation in adaptive immune responses via Immunoinformatics approaches. Infect Genet Evol. 2022 Aug;102:105290.
26. Aziz S, Almajhdi FN, Waqas M, Ullah I, Salim MA, Khan NA, et al. Contriving multi-epitope vaccine ensemble for monkeypox disease using an immunoinformatics approach. Front Immunol. 2022;13.
27. Yousaf M, Ismail S, Ullah A, Bibi S. Immuno-informatics profiling of monkeypox virus cell surface binding protein for designing a next generation multi-valent peptide-based vaccine. Front Immunol. 2022;13:1035924.
28. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20.
29. Oluwagbemi OO, Oladipo EK, Kolawole OM, Oloke JK, Adelusi TI, Irewolede BA, et al. Bioinformatics, Computational Informatics, and Modeling Approaches to the Design of mRNA COVID-19 Vaccine Candidates. Computation. 2022;10(7).
30. Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020;26(3):311–23.
31. Dhople V, Krukemeyer A, Ramamoorthy A. The human beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim Biophys Acta. 2006 Sep;1758(9):1499–512.
32. Ferris LK, Mburu YK, Mathers AR, Fluharty ER, Larregina AT, Ferris RL, et al. Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol. 2013 Feb;133(2):460–8.
33. Fadaka AO, Sibuyi NRS, Martin DR, Goboza M, Klein A, Madiehe AM, et al. Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus. Sci Rep. 2021 Oct;11(1):19707.
34. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007 Jan;8:4.
35. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GPS. Peptide toxicity prediction. Methods Mol Biol. 2015;1268:143–57.
36. Saha S, Raghava GPS. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006;34(suppl_2):W202–9.
37. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990 Oct;215(3):403–10.
38. Grassegger A, Höpfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol. 2004;29(6):584–8.
39. Tur J, Farrera C, Sánchez-Tilló E, Vico T, Guerrero-Gonzalez P, Fernandez-Elorduy A, et al. Induction of CIITA by IFN-γ in macrophages involves STAT1 activation by JAK and JNK. Immunobiology. 2021;226(5):152114.
40. Park H, Kim DE, Ovchinnikov S, Baker D, DiMaio F. Automatic structure prediction of oligomeric assemblies using Robetta in CASP12. Proteins: Structure, Function, and Bioinformatics. 2018;86:283–91.
41. Saleki K, Alijanizadeh P, Javanmehr N, Rezaei N. The role of Toll‐like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management. Med Res Rev. 2024;44(3):1267–325.
42. Saleki K, Mohamadi MH, Banazadeh M, Alijanizadeh P, Javanmehr N, Pourahmad R, et al. In silico design of a TLR4-mediating multiepitope chimeric vaccine against amyotrophic lateral sclerosis via advanced immunoinformatics. J Leukoc Biol. 2022;112(5):1191–207.
43. Yan Y, Zhang D, Zhou P, Li B, Huang SY. HDOCK: a web server for protein–protein and protein–DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 2017;45(W1):W365–73.
44. Laskowski RA, Jabłońska J, Pravda L, Vařeková RS, Thornton JM. PDBsum: Structural summaries of PDB entries. Protein Sci. 2018 Jan;27(1):129–34.
45. Saleki K, Aram C, Alijanizadeh P, Khanmirzaei MH, Vaziri Z, Ramzankhah M, et al. Matrix metalloproteinase/Fas ligand (MMP/FasL) interaction dynamics in COVID-19: An in silico study and neuroimmune perspective. Heliyon. 2024 May 30;10(10).
46. Weng G, Wang E, Wang Z, Liu H, Zhu F, Li D, et al. HawkDock: a web server to predict and analyze the protein–protein complex based on computational docking and MM/GBSA. Nucleic Acids Res. 2019;47(W1):W322–30.
47. Grote A, Hiller K, Scheer M, Münch R, Nörtemann B, Hempel DC, et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005 Jul;33(Web Server issue):W526-31.
48. Pollard C, De Koker S, Saelens X, Vanham G, Grooten J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013 Dec;19(12):705–13.
49. Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1–8.
50. Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatinovich J, Calderhead D, et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol. 2008 Oct;9:90.
51. Kwon H, Kim M, Seo Y, Moon YS, Lee HJ, Lee K, et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials. 2018 Feb;156:172–93.
52. Thomsen M, Lundegaard C, Buus S, Lund O, Nielsen M. MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics. 2013 Sep;65(9):655–65.
53. Reinke S, Thakur A, Gartlan C, Bezbradica JS, Milicic A. Inflammasome-mediated immunogenicity of clinical and experimental vaccine adjuvants. Vaccines (Basel). 2020;8(3):554.
54. Saleki K, Mohamadi M, Alijanizadeh P, Rezaei N. Inflammasome elements in epilepsy and seizures. In: Translational Neuroimmunology, Volume 7. Elsevier; 2023. p. 449–74.
55. Alizadehmoghaddam S, Pourabdolhossein F, Najafzadehvarzi H, Sarbishegi M, Saleki K, Nouri HR. Crocin attenuates the lipopolysaccharide-induced neuroinflammation via expression of aim2 and nlrp1 inflammasome in an experimental model of parkinson’s disease. Heliyon. 2024;10(3).
56. Zhang Y, Zhang JY, Wang FS. Monkeypox outbreak: A novel threat after COVID-19? Mil Med Res. 2022;9(1):29.
57. Atefi A, Ghanaatpisheh A, Ghasemi A, Haghshenas H, Eyvani K, Bakhshi A, et al. Meningitis after COVID-19 vaccination, a systematic review of case reports and case series. BMC Infect Dis. 2024;24(1):1138.
58. Aiman S, Alhamhoom Y, Ali F, Rahman N, Rastrelli L, Khan A, et al. Multi-epitope chimeric vaccine design against emerging Monkeypox virus via reverse vaccinology techniques- a bioinformatics and immunoinformatics approach. Front Immunol. 2022;13.
59. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012 Nov;9(11):1319–30.
60. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.
61. Kandeel M, Morsy MA, Abd El-Lateef HM, Marzok M, El-Beltagi HS, Al Khodair KM, et al. Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention. Int Immunopharmacol. 2023;119:110206.
62. Taha AM, Mahmoud AM, Abouelmagd K, Saed SAA, Khalefa BB, Shah S, et al. Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta-analysis. Health Sci Rep. 2024 Sep;7(9):e70069.
63. Zuiani A, Dulberger CL, De Silva NS, Marquette M, Lu YJ, Palowitch GM, et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell. 2024 Mar;187(6):1363-1373.e12.
64. Gidwani R, Siddiqui S, Prabhavalkar S. REACTIVE NON-REGIONAL LYMPHADENOPATHY FROM THE COVID-19 mRNA VACCINE: A NOVEL SIDE-EFFECT. Vol. 91, The Ulster medical journal. Northern Ireland; 2022. p. 166–7.
65. Yefet R, Friedel N, Tamir H, Polonsky K, Mor M, Hagin D, et al. A35R and H3L are Serological and B Cell Markers for Monkeypox Infection. medRxiv. 2022;
66. Kaur A, Kumar A, Kumari G, Muduli R, Das M, Kundu R, et al. Rational design and computational evaluation of a multi-epitope vaccine for monkeypox virus: Insights into binding stability and immunological memory. Heliyon. 2024;10(16):e36154.
67. Saleki K, Mohamadi MH, Banazadeh M, Alijanizadeh P, Javanmehr N, Pourahmad R, et al. In silico design of a TLR4-mediating multiepitope chimeric vaccine against amyotrophic lateral sclerosis via advanced immunoinformatics. J Leukoc Biol. 2022 Nov;112(5):1191–207.
68. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts. 2018 May;9(1):64–79.
69. Muñoz-Fernández MA, Fernández MA, Fresno M. Activation of human macrophages for the killing of intracellular Trypanosoma cruzi by TNF-alpha and IFN-gamma through a nitric oxide-dependent mechanism. Immunol Lett. 1992 Jun;33(1):35–40.
70. Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, McKean DJ, et al. Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol. 1990 Mar;144(5):1767–76.
71. Gigoux M, Lovato A, Leconte J, Leung J, Sonenberg N, Suh WK. Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation. Mol Immunol. 2014 May;59(1):46–54.
72. Barancheshmeh M, Najafzadehvarzi H, Shokrzadeh N, Aram C. Comparative Analysis of Fennel Essential Oil and Manganese in PCOS Rat Model via modulating miR-145 Expression and Structure-Based Virtual Screening of IGF2R Protein to Address Insulin Resistance and Obesity. Obes Med. 2024;100574.
73. Ullah A, Ahmad S, Ismail S, Afsheen Z, Khurram M, ul Qamar M, et al. Towards A Novel Multi-Epitopes Chimeric Vaccine for Simulating Strong Immune Responses and Protection against Morganella morganii. Int J Environ Res Public Health. 2021;18(20).
74. Khan S, Irfan M, Hameed AR, Ullah A, Abideen SA, Ahmad S, et al. Vaccinomics to design a multi-epitope-based vaccine against monkeypox virus using surface-associated proteins. J Biomol Struct Dyn. 2022 Dec;1–10.
75. Aram C, Alijanizadeh P, Saleki K, Karami L. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches. Biochem Biophys Rep. 2024;39:101745.
76. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005 Dec;26(16):1701–18.
77. López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón P. iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res. 2014 Jul;42(Web Server issue):W271-6.
78. Seyfi S, Azadmehr A, Ezoji K, Nabipour M, Babazadeh A, Saleki K, et al. Mortality in ICU COVID‐19 Patients Is Associated with Neutrophil‐to‐Lymphocyte Ratio (NLR): Utility of NLR as a Promising Immunohematological Marker. Interdiscip Perspect Infect Dis. 2023;2023(1):9048749.
79. Saleki K, Payandeh P, Shakeri M, Pourahmad R, Banazadeh M, Alijanizadeh P, et al. Utilizing immunoinformatics to target brain tumors; an aid to current neurosurgical practice. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
80. Firuzpour F, Saleki K, Aram C, Rezaei N. Nanocarriers in glioblastoma treatment: a neuroimmunological perspective. Rev Neurosci. 2024;(0).
81. Saleki K, Shirzad M, Banazadeh M, Mohamadi MH, Alijanizadeh P, Javanmehr N, et al. Lupus and the nervous system: a neuroimmunoloigcal update on pathogenesis and management of systemic lupus erythematosus with focus on neuropsychiatric SLE. In: Systemic Lupus Erythematosus-Pathogenesis and Management. IntechOpen; 2022.
82. Aram C, Alijanizadeh P, Saleki K, Karami L. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches. Biochem Biophys Rep. 2024;39:101745.
83. Saleki K, Banazadeh M, Saghazadeh A, Rezaei N. Aging, testosterone, and neuroplasticity: friend or foe? Rev Neurosci. 2023;34(3):247–73.
84. Saleki K, Mohamadi MH, Alijanizadeh P, Rezaei N. Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol. 2023;19(11):1361–83.
85. Abdi SAH, Ali A, Sayed SF, Abutahir, Ali A, Alam P. Multi-Epitope-Based Vaccine Candidate for Monkeypox: An In Silico Approach. Vaccines (Basel). 2022 Sep;10(9).
86. Saleki K, Payandeh P, Shakeri M, Pourahmad R, Banazadeh M, Alijanizadeh P, et al. Utilizing Immunoinformatics to Target Brain Tumors; An Aid to Current Neurosurgical Practice. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
87. Tomar N, De RK. Immunoinformatics: a brief review. Methods Mol Biol. 2014;1184:23–55.
88. Guo N, Niu Z, Yan Z, Liu W, Shi L, Li C, et al. Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins. Vaccines (Basel). 2024 Apr;12(4).
89. Saleki K, Alijanizade P, Moradi S, Rahmani A, Banazadeh M, Mohamadi MH, et al. Engineering a novel immunogenic chimera protein utilizing bacterial infections associated with atherosclerosis to induce a deviation in adaptive immune responses via Immunoinformatics approaches. Infection, Genetics and Evolution. 2022;102:105290.
90. Saleki K, Shirzad M, Javanian M, Mohammadkhani S, Alijani MH, Miri N, et al. Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients. Front Immunol. 2022;13:947401.
91. Rahmani A, Baee M, Saleki K, Moradi S, Nouri HR. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. J Biomol Struct Dyn. 2022;40(13):6097–113.
92. Aram C, Alijanizadeh P, Saleki K, Karami L. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches. Biochem Biophys Rep. 2024;39:101745.
93. Saleki K, Aram C, Alijanizadeh P, Khanmirzaei MH, Vaziri Z, Ramzankhah M, et al. Matrix metalloproteinase/Fas ligand (MMP/FasL) interaction dynamics in COVID-19: An in silico study and neuroimmune perspective. Heliyon. 2024;10(10).
94. Latifi R, Azadmehr A, Mosalla S, Saleki K, Hajiaghaee R. Scolicidal effects of the Nicotiana tabacum L. extract at various concentrations and exposure times. J Med Plants. 2022;21(82):111–8.
95. Rong H guo, Zhang X wen, Han M, Sun X, Wu X dan, Lai X zhen, et al. Evidence synthesis of Chinese medicine for monkeypox: Suggestions from other contagious pox-like viral diseases. Front Pharmacol. 2023;14:1121580.
96. Vaziri Z, Saleki K, Aram C, Alijanizadeh P, Pourahmad R, Azadmehr A, et al. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomedicine & Pharmacotherapy. 2023;168:115686.
2. Shchelkunov SN, Totmenin A V, Safronov PF, Mikheev M V, Gutorov V V, Ryazankina OI, et al. Analysis of the monkeypox virus genome. Virology. 2002 Jun;297(2):172–94.
3. Cho CT, Wenner HA. Monkeypox virus. Bacteriol Rev. 1973 Mar;37(1):1–18.
4. Marennikova SS, Moyer RW. Classification of Poxviruses and Brief Characterization of the Genus Orthopoxvirus. In: Orthopoxviruses Pathogenic for Humans. Boston, MA: Springer US; 2005. p. 11–8.
5. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022 Feb;16(2):e0010141.
6. Kozlov M. Monkeypox outbreaks: 4 key questions researchers have. Vol. 606, Nature. England; 2022. p. 238–9.
7. Vogel L. Making sense of monkeypox death rates. CMAJ. 2022 Aug;194(31):E1097.
8. Muniandy T, Abdullah N. Monkeypox: A Comprehensive Review. International Journal of Online Pedagogy and Course Design. 2022;13(1):1–15.
9. Schmidt FI, Bleck CKE, Mercer J. Poxvirus host cell entry. Curr Opin Virol. 2012;2(1):20–7.
10. Banuet-Martinez M, Yang Y, Jafari B, Kaur A, Butt ZA, Chen HH, et al. Monkeypox: a review of epidemiological modelling studies and how modelling has led to mechanistic insight. Epidemiol Infect. 2023 May;151:e121.
11. Zovi A, Ferrara F, Langella R, Vitiello A. Pharmacological Agents with Antiviral Activity against Monkeypox Infection. Int J Mol Sci. 2022 Dec;23(24).
12. Hooper JW, Custer DM, Schmaljohn CS, Schmaljohn AL. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology. 2000 Jan;266(2):329–39.
13. Hou F, Zhang Y, Liu X, Murad Y, Xu J, Yu Z, et al. Novel mRNA vaccines encoding Monkeypox virus M1R and A35R protect mice from a lethal virus challenge. bioRxiv. 2022;
14. Sagdat K, Batyrkhan A, Kanayeva D. Exploring monkeypox virus proteins and rapid detection techniques. Front Cell Infect Microbiol. 2024;14:1414224.
15. Saleki K, Mohamadi MH, Alijanizadeh P, Rezaei N. Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol. 2023;19(11):1361–83.
16. Mohseni Afshar Z, Babazadeh A, Janbakhsh A, Afsharian M, Saleki K, Barary M, et al. Vaccine‐induced immune thrombotic thrombocytopenia after vaccination against Covid‐19: a clinical dilemma for clinicians and patients. Rev Med Virol. 2022;32(2):e2273.
17. Saleki K, Payandeh P, Shakeri M, Pourahmad R, Banazadeh M, Alijanizadeh P, et al. Utilizing immunoinformatics to target brain tumors; an aid to current neurosurgical practice. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
18. Khan S, Khan A, Rehman AU, Ahmad I, Ullah S, Khan AA, et al. Immunoinformatics and structural vaccinology driven prediction of multi-epitope vaccine against Mayaro virus and validation through in-silico expression. Infect Genet Evol. 2019 Sep;73:390–400.
19. Omoniyi AA, Adebisi SS, Musa SA, Nzalak JO, Danborno B, Bauchi ZM, et al. Designing a multi-epitope vaccine against the Lassa virus through reverse vaccinology, subtractive proteomics, and immunoinformatics approaches. Inform Med Unlocked. 2021;25:100683.
20. Rao AK, Petersen BW, Whitehill F, Razeq JH, Isaacs SN, Merchlinsky MJ, et al. Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jun;71(22):734–42.
21. Babkin I V, Babkina IN, Tikunova N V. An Update of Orthopoxvirus Molecular Evolution. Viruses. 2022 Feb;14(2).
22. Home M, Populations S. Interim Clinical Considerations for Use of JYNNEOS and ACAM2000 Vaccines during the 2022 U.S. Mpox Outbreak | Mpox | Poxvirus | CDC. 2023;(Cdc):28–30.
23. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science (1979). 2021;374(6572):abm0829.
24. Al Tbeishat H. Novel In Silico mRNA vaccine design exploiting proteins of M. tuberculosis that modulates host immune responses by inducing epigenetic modifications. Sci Rep. 2022 Mar;12(1):4645.
25. Saleki K, Alijanizade P, Moradi S, Rahmani A, Banazadeh M, Mohamadi MH, et al. Engineering a novel immunogenic chimera protein utilizing bacterial infections associated with atherosclerosis to induce a deviation in adaptive immune responses via Immunoinformatics approaches. Infect Genet Evol. 2022 Aug;102:105290.
26. Aziz S, Almajhdi FN, Waqas M, Ullah I, Salim MA, Khan NA, et al. Contriving multi-epitope vaccine ensemble for monkeypox disease using an immunoinformatics approach. Front Immunol. 2022;13.
27. Yousaf M, Ismail S, Ullah A, Bibi S. Immuno-informatics profiling of monkeypox virus cell surface binding protein for designing a next generation multi-valent peptide-based vaccine. Front Immunol. 2022;13:1035924.
28. Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20.
29. Oluwagbemi OO, Oladipo EK, Kolawole OM, Oloke JK, Adelusi TI, Irewolede BA, et al. Bioinformatics, Computational Informatics, and Modeling Approaches to the Design of mRNA COVID-19 Vaccine Candidates. Computation. 2022;10(7).
30. Linares-Fernández S, Lacroix C, Exposito JY, Verrier B. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020;26(3):311–23.
31. Dhople V, Krukemeyer A, Ramamoorthy A. The human beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim Biophys Acta. 2006 Sep;1758(9):1499–512.
32. Ferris LK, Mburu YK, Mathers AR, Fluharty ER, Larregina AT, Ferris RL, et al. Human beta-defensin 3 induces maturation of human langerhans cell-like dendritic cells: an antimicrobial peptide that functions as an endogenous adjuvant. J Invest Dermatol. 2013 Feb;133(2):460–8.
33. Fadaka AO, Sibuyi NRS, Martin DR, Goboza M, Klein A, Madiehe AM, et al. Immunoinformatics design of a novel epitope-based vaccine candidate against dengue virus. Sci Rep. 2021 Oct;11(1):19707.
34. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007 Jan;8:4.
35. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Raghava GPS. Peptide toxicity prediction. Methods Mol Biol. 2015;1268:143–57.
36. Saha S, Raghava GPS. AlgPred: prediction of allergenic proteins and mapping of IgE epitopes. Nucleic Acids Res. 2006;34(suppl_2):W202–9.
37. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990 Oct;215(3):403–10.
38. Grassegger A, Höpfl R. Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol. 2004;29(6):584–8.
39. Tur J, Farrera C, Sánchez-Tilló E, Vico T, Guerrero-Gonzalez P, Fernandez-Elorduy A, et al. Induction of CIITA by IFN-γ in macrophages involves STAT1 activation by JAK and JNK. Immunobiology. 2021;226(5):152114.
40. Park H, Kim DE, Ovchinnikov S, Baker D, DiMaio F. Automatic structure prediction of oligomeric assemblies using Robetta in CASP12. Proteins: Structure, Function, and Bioinformatics. 2018;86:283–91.
41. Saleki K, Alijanizadeh P, Javanmehr N, Rezaei N. The role of Toll‐like receptors in neuropsychiatric disorders: Immunopathology, treatment, and management. Med Res Rev. 2024;44(3):1267–325.
42. Saleki K, Mohamadi MH, Banazadeh M, Alijanizadeh P, Javanmehr N, Pourahmad R, et al. In silico design of a TLR4-mediating multiepitope chimeric vaccine against amyotrophic lateral sclerosis via advanced immunoinformatics. J Leukoc Biol. 2022;112(5):1191–207.
43. Yan Y, Zhang D, Zhou P, Li B, Huang SY. HDOCK: a web server for protein–protein and protein–DNA/RNA docking based on a hybrid strategy. Nucleic Acids Res. 2017;45(W1):W365–73.
44. Laskowski RA, Jabłońska J, Pravda L, Vařeková RS, Thornton JM. PDBsum: Structural summaries of PDB entries. Protein Sci. 2018 Jan;27(1):129–34.
45. Saleki K, Aram C, Alijanizadeh P, Khanmirzaei MH, Vaziri Z, Ramzankhah M, et al. Matrix metalloproteinase/Fas ligand (MMP/FasL) interaction dynamics in COVID-19: An in silico study and neuroimmune perspective. Heliyon. 2024 May 30;10(10).
46. Weng G, Wang E, Wang Z, Liu H, Zhu F, Li D, et al. HawkDock: a web server to predict and analyze the protein–protein complex based on computational docking and MM/GBSA. Nucleic Acids Res. 2019;47(W1):W322–30.
47. Grote A, Hiller K, Scheer M, Münch R, Nörtemann B, Hempel DC, et al. JCat: a novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res. 2005 Jul;33(Web Server issue):W526-31.
48. Pollard C, De Koker S, Saelens X, Vanham G, Grooten J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med. 2013 Dec;19(12):705–13.
49. Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK, Ahn JY, et al. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Mol Cell Toxicol. 2022;18(1):1–8.
50. Tcherepanova IY, Adams MD, Feng X, Hinohara A, Horvatinovich J, Calderhead D, et al. Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion. BMC Mol Biol. 2008 Oct;9:90.
51. Kwon H, Kim M, Seo Y, Moon YS, Lee HJ, Lee K, et al. Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine. Biomaterials. 2018 Feb;156:172–93.
52. Thomsen M, Lundegaard C, Buus S, Lund O, Nielsen M. MHCcluster, a method for functional clustering of MHC molecules. Immunogenetics. 2013 Sep;65(9):655–65.
53. Reinke S, Thakur A, Gartlan C, Bezbradica JS, Milicic A. Inflammasome-mediated immunogenicity of clinical and experimental vaccine adjuvants. Vaccines (Basel). 2020;8(3):554.
54. Saleki K, Mohamadi M, Alijanizadeh P, Rezaei N. Inflammasome elements in epilepsy and seizures. In: Translational Neuroimmunology, Volume 7. Elsevier; 2023. p. 449–74.
55. Alizadehmoghaddam S, Pourabdolhossein F, Najafzadehvarzi H, Sarbishegi M, Saleki K, Nouri HR. Crocin attenuates the lipopolysaccharide-induced neuroinflammation via expression of aim2 and nlrp1 inflammasome in an experimental model of parkinson’s disease. Heliyon. 2024;10(3).
56. Zhang Y, Zhang JY, Wang FS. Monkeypox outbreak: A novel threat after COVID-19? Mil Med Res. 2022;9(1):29.
57. Atefi A, Ghanaatpisheh A, Ghasemi A, Haghshenas H, Eyvani K, Bakhshi A, et al. Meningitis after COVID-19 vaccination, a systematic review of case reports and case series. BMC Infect Dis. 2024;24(1):1138.
58. Aiman S, Alhamhoom Y, Ali F, Rahman N, Rastrelli L, Khan A, et al. Multi-epitope chimeric vaccine design against emerging Monkeypox virus via reverse vaccinology techniques- a bioinformatics and immunoinformatics approach. Front Immunol. 2022;13.
59. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012 Nov;9(11):1319–30.
60. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79.
61. Kandeel M, Morsy MA, Abd El-Lateef HM, Marzok M, El-Beltagi HS, Al Khodair KM, et al. Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention. Int Immunopharmacol. 2023;119:110206.
62. Taha AM, Mahmoud AM, Abouelmagd K, Saed SAA, Khalefa BB, Shah S, et al. Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta-analysis. Health Sci Rep. 2024 Sep;7(9):e70069.
63. Zuiani A, Dulberger CL, De Silva NS, Marquette M, Lu YJ, Palowitch GM, et al. A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease. Cell. 2024 Mar;187(6):1363-1373.e12.
64. Gidwani R, Siddiqui S, Prabhavalkar S. REACTIVE NON-REGIONAL LYMPHADENOPATHY FROM THE COVID-19 mRNA VACCINE: A NOVEL SIDE-EFFECT. Vol. 91, The Ulster medical journal. Northern Ireland; 2022. p. 166–7.
65. Yefet R, Friedel N, Tamir H, Polonsky K, Mor M, Hagin D, et al. A35R and H3L are Serological and B Cell Markers for Monkeypox Infection. medRxiv. 2022;
66. Kaur A, Kumar A, Kumari G, Muduli R, Das M, Kundu R, et al. Rational design and computational evaluation of a multi-epitope vaccine for monkeypox virus: Insights into binding stability and immunological memory. Heliyon. 2024;10(16):e36154.
67. Saleki K, Mohamadi MH, Banazadeh M, Alijanizadeh P, Javanmehr N, Pourahmad R, et al. In silico design of a TLR4-mediating multiepitope chimeric vaccine against amyotrophic lateral sclerosis via advanced immunoinformatics. J Leukoc Biol. 2022 Nov;112(5):1191–207.
68. Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases. Biomol Concepts. 2018 May;9(1):64–79.
69. Muñoz-Fernández MA, Fernández MA, Fresno M. Activation of human macrophages for the killing of intracellular Trypanosoma cruzi by TNF-alpha and IFN-gamma through a nitric oxide-dependent mechanism. Immunol Lett. 1992 Jun;33(1):35–40.
70. Ruegemer JJ, Ho SN, Augustine JA, Schlager JW, Bell MP, McKean DJ, et al. Regulatory effects of transforming growth factor-beta on IL-2- and IL-4-dependent T cell-cycle progression. J Immunol. 1990 Mar;144(5):1767–76.
71. Gigoux M, Lovato A, Leconte J, Leung J, Sonenberg N, Suh WK. Inducible costimulator facilitates T-dependent B cell activation by augmenting IL-4 translation. Mol Immunol. 2014 May;59(1):46–54.
72. Barancheshmeh M, Najafzadehvarzi H, Shokrzadeh N, Aram C. Comparative Analysis of Fennel Essential Oil and Manganese in PCOS Rat Model via modulating miR-145 Expression and Structure-Based Virtual Screening of IGF2R Protein to Address Insulin Resistance and Obesity. Obes Med. 2024;100574.
73. Ullah A, Ahmad S, Ismail S, Afsheen Z, Khurram M, ul Qamar M, et al. Towards A Novel Multi-Epitopes Chimeric Vaccine for Simulating Strong Immune Responses and Protection against Morganella morganii. Int J Environ Res Public Health. 2021;18(20).
74. Khan S, Irfan M, Hameed AR, Ullah A, Abideen SA, Ahmad S, et al. Vaccinomics to design a multi-epitope-based vaccine against monkeypox virus using surface-associated proteins. J Biomol Struct Dyn. 2022 Dec;1–10.
75. Aram C, Alijanizadeh P, Saleki K, Karami L. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches. Biochem Biophys Rep. 2024;39:101745.
76. Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, Berendsen HJC. GROMACS: fast, flexible, and free. J Comput Chem. 2005 Dec;26(16):1701–18.
77. López-Blanco JR, Aliaga JI, Quintana-Ortí ES, Chacón P. iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res. 2014 Jul;42(Web Server issue):W271-6.
78. Seyfi S, Azadmehr A, Ezoji K, Nabipour M, Babazadeh A, Saleki K, et al. Mortality in ICU COVID‐19 Patients Is Associated with Neutrophil‐to‐Lymphocyte Ratio (NLR): Utility of NLR as a Promising Immunohematological Marker. Interdiscip Perspect Infect Dis. 2023;2023(1):9048749.
79. Saleki K, Payandeh P, Shakeri M, Pourahmad R, Banazadeh M, Alijanizadeh P, et al. Utilizing immunoinformatics to target brain tumors; an aid to current neurosurgical practice. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
80. Firuzpour F, Saleki K, Aram C, Rezaei N. Nanocarriers in glioblastoma treatment: a neuroimmunological perspective. Rev Neurosci. 2024;(0).
81. Saleki K, Shirzad M, Banazadeh M, Mohamadi MH, Alijanizadeh P, Javanmehr N, et al. Lupus and the nervous system: a neuroimmunoloigcal update on pathogenesis and management of systemic lupus erythematosus with focus on neuropsychiatric SLE. In: Systemic Lupus Erythematosus-Pathogenesis and Management. IntechOpen; 2022.
82. Aram C, Alijanizadeh P, Saleki K, Karami L. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches. Biochem Biophys Rep. 2024;39:101745.
83. Saleki K, Banazadeh M, Saghazadeh A, Rezaei N. Aging, testosterone, and neuroplasticity: friend or foe? Rev Neurosci. 2023;34(3):247–73.
84. Saleki K, Mohamadi MH, Alijanizadeh P, Rezaei N. Neurological adverse effects of chimeric antigen receptor T-cell therapy. Expert Rev Clin Immunol. 2023;19(11):1361–83.
85. Abdi SAH, Ali A, Sayed SF, Abutahir, Ali A, Alam P. Multi-Epitope-Based Vaccine Candidate for Monkeypox: An In Silico Approach. Vaccines (Basel). 2022 Sep;10(9).
86. Saleki K, Payandeh P, Shakeri M, Pourahmad R, Banazadeh M, Alijanizadeh P, et al. Utilizing Immunoinformatics to Target Brain Tumors; An Aid to Current Neurosurgical Practice. Interventional Pain Medicine and Neuromodulation. 2022;2(1).
87. Tomar N, De RK. Immunoinformatics: a brief review. Methods Mol Biol. 2014;1184:23–55.
88. Guo N, Niu Z, Yan Z, Liu W, Shi L, Li C, et al. Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins. Vaccines (Basel). 2024 Apr;12(4).
89. Saleki K, Alijanizade P, Moradi S, Rahmani A, Banazadeh M, Mohamadi MH, et al. Engineering a novel immunogenic chimera protein utilizing bacterial infections associated with atherosclerosis to induce a deviation in adaptive immune responses via Immunoinformatics approaches. Infection, Genetics and Evolution. 2022;102:105290.
90. Saleki K, Shirzad M, Javanian M, Mohammadkhani S, Alijani MH, Miri N, et al. Serum soluble Fas ligand is a severity and mortality prognostic marker for COVID-19 patients. Front Immunol. 2022;13:947401.
91. Rahmani A, Baee M, Saleki K, Moradi S, Nouri HR. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2. J Biomol Struct Dyn. 2022;40(13):6097–113.
92. Aram C, Alijanizadeh P, Saleki K, Karami L. Development of an ancestral DC and TLR4-inducing multi-epitope peptide vaccine against the spike protein of SARS-CoV and SARS-CoV-2 using the advanced immunoinformatics approaches. Biochem Biophys Rep. 2024;39:101745.
93. Saleki K, Aram C, Alijanizadeh P, Khanmirzaei MH, Vaziri Z, Ramzankhah M, et al. Matrix metalloproteinase/Fas ligand (MMP/FasL) interaction dynamics in COVID-19: An in silico study and neuroimmune perspective. Heliyon. 2024;10(10).
94. Latifi R, Azadmehr A, Mosalla S, Saleki K, Hajiaghaee R. Scolicidal effects of the Nicotiana tabacum L. extract at various concentrations and exposure times. J Med Plants. 2022;21(82):111–8.
95. Rong H guo, Zhang X wen, Han M, Sun X, Wu X dan, Lai X zhen, et al. Evidence synthesis of Chinese medicine for monkeypox: Suggestions from other contagious pox-like viral diseases. Front Pharmacol. 2023;14:1121580.
96. Vaziri Z, Saleki K, Aram C, Alijanizadeh P, Pourahmad R, Azadmehr A, et al. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomedicine & Pharmacotherapy. 2023;168:115686.
| Files | ||
| Issue | Vol 8, No 4 (2025) | |
| Section | Original Article | |
| DOI | https://doi.org/10.18502/igj.v8i4.20101 | |
| Keywords | ||
| computational immunology Immunoinformatic Monkeypox Molecular Dynamics Polytopic Vaccine Reverse Vaccinology | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Aram C, Saleki K, Mazloomi A, Rezaei N. Design of a Trivalent DC-inducing mRNA Vaccine Against Monkeypox, Cowpox, and Vaccinia Viruses: A Computational Approach. Immunol Genet J. 2025;8(4):332-356.
